ATLASATLAS fair value
DKK 489.11
Below fair value · 47% discount
Range: DKK 310–DKK 588Fair valuePrice
Novo Nordisk (NOVO-B.CO)
Novo Nordisk stock price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - General · Nasdaq Copenhagen · Denmark
DKK 259.50▼ -0.36%
Prices as of Oct 27, 2026 · DKK
Chance of rising in 1 month
50%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Novo Nordisk in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Novo Nordisk
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS estimates Novo Nordisk's fair value at about DKK 489.11 per share (reasonable range: DKK 309.61 to DKK 587.86). At DKK 259.50, the stock trades 47% below it.
It is calculated with a blend of a discounted cash-flow model and peer valuation multiples. Confidence in the estimate is medium. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives Novo Nordisk a 50% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between DKK 244.70 and DKK 275.66; in 9 out of 10, between DKK 220.17 and DKK 306.37. Estimated annual volatility is 30%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- DKK 1.1T
- Market cap (USD)
- $171B
- P/E ratio
- 9.8
- Dividend yield
- 4.44%
- 52-week high
- DKK 409.95
- 52-week low
- DKK 224.25
- Revenue (12 months)
- DKK 329B
- Gross margin
- 82.0%
- Operating margin
- 42.5%
- Net margin
- 35.4%
- Beta
- 0.38
What this means
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. Novo Nordisk sits below fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks NOVO-B.CO has traded between DKK 224.25 and DKK 409.95. Today it is 36.7% below that high and 16% above its low.
On the business: net margin is 35.4%; it trades at 9.8 times earnings.
Its beta is 0.38: it tends to move less than the market.
About the company
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease.
Want to see everything about Novo Nordisk?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What is Novo Nordisk (NOVO-B.CO) fair value?
About DKK 489.11 per share according to ATLAS (reasonable range: DKK 309.61 to DKK 587.86). With the stock at DKK 259.50, it is 47% below it.
What is the chance NOVO-B.CO goes up next month?
50%: close to a coin flip. In half of the simulated outcomes, NOVO-B.CO ends the month between DKK 244.70 and DKK 275.66.
How big is Novo Nordisk and what is its P/E ratio?
Novo Nordisk's market capitalization is DKK 1.1T. Its price-to-earnings (P/E) ratio is 9.8: you pay DKK 9.75 for each DKK 1.00 of yearly earnings.
Does Novo Nordisk pay a dividend?
Yes. NOVO-B.CO's current dividend yield is 4.44% at today's price (DKK 259.50).
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer